CHMP Recommends Otsuka Pharmaceutical Co., Ltd.'s Deltyba™ (Delamanid) For EU Approval For Treatment Of Multidrug-Resistant Tuberculosis (MDR-TB) In Combination With Optimized Background Regimen (OBR)